Clicky

Heron Therapeutics, Inc. (HRTX)

Description: Heron Therapeutics, Inc., a specialty pharmaceutical company, develops product candidates using its proprietary Biochronomer polymer-based drug delivery platform. The company's drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that should be injected once or twice per day to products that need to be injected once every one or two weeks. Its lead product candidate, Sustol, is developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting for patients undergoing emetogenic chemotherapy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Redwood City, California.


Keywords: Medicine Pharmaceutical Clinical Medicine Occupational Safety And Health Oncology Cancer Treatment Chemotherapy Drug Delivery Antineoplastic Drugs Nausea

Home Page: www.herontx.com

HRTX Technical Analysis

4242 Campus Point Court
San Diego, CA 92121
United States
Phone: 858 251 4400


Officers

Name Title
Dr. Barry D. Quart Pharm.D. Chairman & CEO
Mr. John W. Poyhonen Pres & Chief Commercial Officer
Mr. David L. Szekeres Exec. VP & COO
Ms. Lisa Peraza VP & Chief Accounting Officer
Ms. Kimberly J. Manhard Exec. VP of Drug Devel. & Director
Mr. Sean T. Ristine Sr. VP of HR
Dr. Thomas B. Ottoboni Ph.D. Chief Scientific Officer and Sr. VP of Pharmaceutical & Translational Sciences
Mr. Michael E. Mathews Sr. VP of Acute Care
Dr. Chris M. Storgard Chief Medical Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 13.8217
Price-to-Sales TTM: 3.072
IPO Date: 1987-08-26
Fiscal Year End: December
Full Time Employees: 302
Back to stocks